Dial-in Number

  • One tap mobile
    +13126266799,,3231998494# US (Chicago)
    +13462487799,,3231998494# US (Houston)
  • Dial by your location
    +1 312 626 6799 US (Chicago)
    +1 346 248 7799 US (Houston)
    +1 669 900 6833 US (San Jose)
    +1 929 436 2866 US (New York)
    +1 253 215 8782 US
    +1 301 715 8592 US
    Meeting ID: 323 199 8494
    Find your local number:

Web session

HL7 Antitrust Policy

Professional Associations, such as HL7, which bring together competing entities are subject to strict scrutiny under applicable antitrust laws. HL7 recognizes that the antitrust laws were enacted to promote fairness in competition and, as such, supports laws against monopoly and restraints of trade and their enforcement. Each individual participating in HL7 meetings and conferences, regardless of venue, is responsible for knowing the contents of and adhering to the HL7 Antitrust Policy as stated in §05.01 of the Governance and Operations Manual (GOM).


Melva Peters (Chair)Jenaker Consulting
John HatemIndependent Consultant
Stephen ChuADHA
Tim McNeilSurescript
Scott RobertsonKaiser Permanente
Jean DuteauDuteau Design
Joseph Quinn Smile CDR
Corey SpearsMITRE
Christof GessnerHL7 Germany
Frank McKinneyPOCP

Agenda Items and Notes

Meeting Notes from previous meeting

Project Review

Project Proposals

Project Scope Statements

Discussion of MedicationKnowledge changes (Jean Duteau)

  • - no update
    • have already taken in to account changes from BR&R
      • don't use ingredient 
      • reference to MedicinalProductDefinition

Catalog Updates (John Hatem)

    • targeting May 2022 ballot for next Catalog IG
      • dependent on FMG to provide a plan for FHIR IGs in R5 - can create an IG against 4.6.0 but not current build
    • working on JIRA issues for Device Definition

Workflow Update (John Hatem) 

- not meeting this week. Next meeting is November 29th 

Healthcare Product Update (John Hatem)

    • HCP meeting discussed Scope and Boundaries for the Biologically Derived Product resource.  Pharmacy needs clarification I believe on what items will be ordered via the Biologically Derived Product Resource. The items that Pharmacy will need to focus on are: 
    • Need to determine if we will reference biologically derived product from our resources - if there is a chance that any biologically derived product could be ordered from Pharmacy, then our resources need to be updated to reference the resource.
    • Pharmacy needs to review resources to determine what resources should be referenced - add a tracker

NCPDP Updates (NCPDP Members)

Consultant Pharmacist Consult Note Updated PSS - Scott and Shelly. See PSS-1884 - Getting issue details... STATUS  

Scott will update and it will come back to Pharmacy for review

Global Supply Chain Project (Scott)

  • heard back from Jose - will try to re-invigorate the project

Medication List Guidance project (John)

  • - no updates this week


Pharmacy Templates

  • waiting for requirements from Christof and then will decide on next steps for new version
  • Still waiting for approval of change request in Europe
    • additional elements to be added - part relationship

PDex Formulary (Corey)

  • Approval of IG for ballot - vote November 29

FHIR (Group)

BR&R managed resources review

  • no recent meetings

New Resource - FormularyItem

  • January 21 - new resource proposal deadline for May 2022 ballot

Preparation for Normative

  • Melva to work with John about QA needed

Trackers - link to pharmacy unresolved Jira trackers (see trackers for details / resolutions)

Any Other Business

  • Medication List Project from EHR 
    • Reducing Clinician Burden Project in EHR - sub project around Medication Reconciliation processes
      • have questions about what they are doing - EHR has not reached out to Pharmacy about this project
      • have asked them to come and talk to us about this project

Next meeting

  • reach out to IPA team to have them come to an upcoming call to discuss medication related content